Cirba v. Janssen

March 2015

Result: Jury finds negligence but not causation

In the second Risperdal trial, the jury reached a split decision. While the jury found the J&J did “negligently fail to adequately warn physicians/health care providers of the extent of the risk of Gynecomastia stemming from the use of Risperdal,” they did not find defendants’ “negligence a substantial factor in bringing about” the plaintiff’s gynecomastia. As a result, no damages were awarded.

Public Records:

Press Reports

PA Superior Court Reverses Risperdal Defense Verdict as Court Strikes Janssen Pharmaceuticals Only Favorable Jury Verdict | MassTortNexus.com | November 17, 2017

J&J's Janssen scores partial victory in second Risperdal trial | Reuters.com | March 20, 2015